Biotech Startups

Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS. Founded as a spin-off from VIB and KU Leuven, it focuses on drug development for currently untreatable complex neurological diseases.

5 investors

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders. The company targets both rare and prevalent brain diseases, using biomarker-driven development strategies to demonstrate on-target activity early in clinical trials.

5 investors

5 investors

Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases. The company has three clinical-stage programs targeting myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.

5 investors

Baebies develops multifunctional syndromic diagnostic testing using proprietary digital microfluidics, integrating molecular, immunoassay, chemistry, and coagulation testing into a single compact platform (FINDER) that runs on small-volume samples. Its products serve hospitals, clinics, pharmacies, and decentralized care settings for patients of all ages, having started with newborn and pediatric diagnostics.

5 investors

Basepair is a SaaS bioinformatics platform that provisions in a customer's own AWS account to store and analyze genomic and next-generation sequencing (NGS) data without moving it, offering point-and-click and API-driven workflows plus interactive visualization. It serves healthcare and life-science research teams, including bench scientists and bioinformaticians, with prebuilt pipelines for genomics, transcriptomics, and epigenomics.

5 investors

Basepaws offers at-home DNA test kits for cats and dogs, using an oral swab to provide digital reports on breed mix, genetic health markers, oral health, and physical traits. The service is aimed at pet owners who want data to make informed decisions with their veterinarian about their pet's health.

5 investors

Beren is a public benefit corporation developing novel medicines in partnership with patients, caregivers, clinicians, and health systems. It focuses on advancing biology and chemistry to address the root causes of diseases.

5 investors

Big Hat Bio develops therapeutics under development across multiple programs. The company is a STEM-focused team working on therapeutic discovery and development.

5 investors

BioProtect develops a balloon spacer used in radiation therapy to create uniform anterior-posterior spacing and reduce radiation dose to surrounding tissue during treatments such as prostate cancer radiotherapy. Positioned as the first non-gel spacer for modern radiation therapies, it targets physicians and patients undergoing hypofractionated and SBRT treatments.

5 investors

Bio Protocol is a decentralized science (DeSci) platform where people can fund, develop and govern tokenized early-stage scientific research from universities, companies and researchers. It offers token-based fundraising, staking rewards, and a scientific AI agent framework, supporting an ecosystem of biotech DAOs focused on areas such as longevity, women's health, and rare diseases.

5 investors

BioAesthetics develops NACgraft, a cell-free, collagen-rich nipple-areolar complex graft that a surgeon applies so the patient's own cells integrate it into living nipple and areola tissue. It targets breast cancer survivors who have undergone mastectomies and lost their nipples, operating in the biomaterials and medical device field.

5 investors

Biographica (Graphica) uses multi-modal machine learning and high-throughput sequencing to identify and prioritize genetic targets for crop gene-editing, working with trait developers to design effective edits. It serves agricultural biotech companies developing more productive, nutritious, and climate-resilient crops.

5 investors

BiomeSense builds an AI-enabled platform combining hardware (GutLab) and bioinformatics (MetaBiome) to continuously generate and analyze gut microbiome data. It serves scientists, institutions, and companies conducting clinical research on the microbiome for personalized biomarker discovery and product development.

5 investors

BioReact provides a data integration platform that unifies experimental data from bioreactors, laboratory instruments, and omics workflows into a standardized, AI-ready format for bioprocess development. The platform serves scientists in synthetic biology, cell therapy, biologics, and precision fermentation who need to consolidate fragmented scientific data for analytics and machine learning.

5 investors

BIOS develops neural digital therapy technology to deliver treatments for neurological conditions. The company combines neural engineering with AI and machine learning to improve healthcare outcomes and restore patient control over bodily function.

5 investors

Blank Bio develops RNA foundation models for precision oncology, helping pharmaceutical companies identify the right patients for clinical trials and predict disease progression using bulk RNA-seq data. The company applies AI to patient selection and disease trajectory modeling to improve clinical trial outcomes.

5 investors

Bond Pets develops brewed meat proteins using precision fermentation for pet food products that are marketed as better for pets, farm animals, and the planet.

5 investors

Brixton Bio develops Reneurx therapy, a treatment aimed at providing long-lasting pain relief for up to six months from a single administration. The company operates in the biotech and therapeutics space focused on pain control.

5 investors

Broken String Biosciences develops tools for genome-wide on- and off-target analysis in gene editing, enabling in-house detection and characterization of gene editing-induced DNA breaks. It serves gene editing therapeutic developers working from discovery through IND across diverse cell types and nuclease systems.

5 investors

Bugbiome develops crop protection products for farmers that aim to work with natural systems. The company focuses on sustainable agriculture and reducing the environmental impact of farming.

5 investors

Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy. The medical device is designed to be adaptable to individual patient needs and was developed in collaboration with Mayo Clinic.

5 investors

Caladan Bio develops high-throughput benchtop bioreactor hardware and software for laboratory bioprocessing, enabling faster experimentation and lower costs for biotech R&D teams. The company integrates bioreactor equipment with AI-driven process modeling software to support strain optimization and scale-up workflows.

5 investors

CarbonBridge develops a proprietary direct gas bioprocessing platform for bioreactor operations that eliminates solubility barriers without traditional equipment like spargers or agitators. The platform serves biotech and industrial biology companies seeking higher productivity and faster response times in bioprocessing.

5 investors